GHK-Cu topical cream versus injectable peptide: what changes?

What to look for in a serum

A skin-care label may name copper tripeptide-1, another name used for GHK-Cu. Check the complete product and its directions: other ingredients, the formulation and your skin can also affect tolerability. A peptide name or percentage alone cannot predict a result. If a product irritates your skin, stop using it and ask a pharmacist or clinician for advice. For the evidence and other product types, see GHK-Cu, GLOW and KLOW compared.

For an everyday skin-care question, see what to expect from a copper-peptide serum.5

Topical evidence has a narrow scope

A topical study may measure hydration, appearance or another local outcome. It does not establish that the same molecule, concentration or endpoint applies after injection. Cosmetic marketing language can also describe appearance rather than a validated treatment outcome. For a general explanation, see why the route of use matters.

For example, a 2006 randomized comparison of skin-care regimens after facial laser treatment had 13 completers. Blinded and computer assessments did not find a statistically significant difference in redness, wrinkles or overall skin quality, while participants rated skin-quality improvement higher with the copper-peptide regimen. Separately, a 12-week study in 18 adults applied GHK-Cu serum to one eyebrow and a comparison serum to the other; the average count at week 12 was slightly higher on the treated side. This comparison is not a count of new hairs or a baseline-adjusted treatment effect. Neither study establishes the effect of an injectable product, or that every topical formulation works. Read the details and limitations in the GHK-Cu profile. For the separate eyebrow and scalp studies, see what the hair research measured.156

Injection changes safety and pharmacology

An injection bypasses the skin barrier and can expose the body to a larger or different amount. FDA says compounded injectable drugs containing GHK-Cu may pose an immune-response risk related to potential aggregation and peptide impurities; human safety data are limited. Sterility and endotoxin control are also important product-quality questions.13

If you have already injected a product and the skin is painful, hot and swollen, seek urgent medical advice; these signs can have different causes, including infection. Sudden swelling of the lips, mouth, tongue or throat, or difficulty breathing, needs emergency help immediately. Tell the clinician what you used and, if available, bring its packaging. See injection-site reactions and when to seek help.89

What to ask of a claim

Name the exact formulation and route, identify the population and outcome studied, and check whether a regulator assessed that product. Do not treat a topical cosmetic, a research material and a compounded injection as interchangeable.24

What FDA plans to review in 2027

FDA says it plans to convene its Pharmacy Compounding Advisory Committee before the end of February 2027 to discuss GHK-Cu, cathelicidin LL-37, dihexa acetate, melanotan II and pegylated mechano growth factor for possible inclusion on the section 503A bulk substances list. As checked on 5 November 2026, FDA says the meeting time and location are to be scheduled. The committee gives non-binding advice: discussion does not mean inclusion, FDA approval, proven benefit, or that the HHS interim policy will be extended to these substances.7